Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities.
The most efficacious Mn(III) porphyrinic (MnPs) scavengers of reactive species have positive charges close to the Mn site, whereby they afford thermodynamic and electrostatic facilitation for the reaction with negatively charged species such as O                            (2)                                      (•-)                          and ONOO(-). Those are Mn(III) meso tetrakis(N-alkylpyridinium-2-yl)porphyrins, more specifically MnTE-2-PyP(5+) (AEOL10113) and MnTnHex-2-PyP(5+) (where alkyls are ethyl and n-hexyl, respectively), and their imidazolium analog, MnTDE-2-ImP(5+) (AEOL10150, Mn(III) meso tetrakis(N,N'-diethylimidazolium-2-yl) porphyrin). The efficacy of MnPs in vivo is determined not only by the compound antioxidant potency, but also by its bioavailability. The former is greatly affected by the lipophilicity, size, structure, and overall shape of the compound. These porphyrins have the ability to both eliminate reactive oxygen species and impact the progression of oxidative stress-dependent signaling events. This will effectively lead to the regulation of redox-dependent transcription factors and the suppression of secondary inflammatory- and oxidative stress-mediated immune responses. We have reported on the inhibition of major transcription factors HIF-1α, AP-1, SP-1, and NF-κB by Mn porphyrins. While the prevailing mechanistic view of the suppression of transcription factors activation is via antioxidative action (presumably in cytosol), the pro-oxidative action of MnPs in suppressing NF-κB activation in nucleus has been substantiated. The magnitude of the effect is dependent upon the electrostatic (porphyrin charges) and thermodynamic factors (porphyrin redox ability). The pro-oxidative action of MnPs has been suggested to contribute at least in part to the in vitro anticancer action of MnTE-2-PyP(5+) in the presence of ascorbate, and in vivo when combined with chemotherapy of lymphoma. Given the remarkable therapeutic potential of metalloporphyrins, future studies are warranted to further our understanding of in vivo action/s of Mn porphyrins, particularly with respect to their subcellular distribution.
Batinic-Haberle
Ines
I
Department of Radiation Oncology, Duke University Medical Center, 281b/285 MSRB I, Durham, NC 27710, USA. ibatinic@duke.edu
Spasojevic
Ivan
I
Tse
Hubert M
HM
Tovmasyan
Artak
A
Rajic
Zrinka
Z
St Clair
Daret K
DK
Vujaskovic
Zeljko
Z
Dewhirst
Mark W
MW
Piganelli
Jon D
JD
D000818:Animals; D006801:Humans; D008345:Manganese / Q000737:chemistry / Q000378:metabolism*; D008665:Metalloporphyrins / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects*; D015533:Transcriptional Activation / Q000187:drug effects*
D008665:Metalloporphyrins; D008345:Manganese
J Biol Chem. 2007 Jul 13;282(28):20416-24
17452333
J Inorg Biochem. 2006 Nov;100(11):1897-902
16965820
J Biol Chem. 2003 Feb 28;278(9):6831-7
12475974
Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H2719-25
17660393
Amino Acids. 2012 Jan;42(1):117-28
20559672
J Biol Chem. 1994 Sep 23;269(38):23471-6
8089112
Free Radic Biol Med. 2008 Mar 15;44(6):982-9
18082148
Dalton Trans. 2006 Jan 28;(4):617-24
16402149
Cancer Res. 2000 Jul 15;60(14):3927-39
10919671
Free Radic Biol Med. 2009 Sep 15;47(6):675-83
19527783
J Am Chem Soc. 2008 Apr 9;130(14):4604-6
18341341
J Inorg Biochem. 2007 Nov;101(11-12):1875-82
17723242
Expert Opin Investig Drugs. 2006 Nov;15(11):1383-93
17040198
Inorg Chem. 2001 Feb 12;40(4):726-39
11225116
Cancer Res. 2001 Aug 15;61(16):6082-8
11507057
J Am Chem Soc. 1973 May 2;95(9):2786-90
4632912
FASEB J. 2005 Oct;19(12):1734-6
16081500
Am J Physiol Cell Physiol. 2008 Oct;295(4):C849-68
18684987
Free Radic Biol Med. 2004 Jan 15;36(2):233-47
14744635
Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):1028-31
18439417
Free Radic Biol Med. 2009 Oct 1;47(7):917-23
19631268
Free Radic Biol Med. 2009 Jul 1;47(1):72-8
19361553
Chem Res Toxicol. 1999 May;12(5):442-9
10328755
Nat Rev Drug Discov. 2009 Jul;8(7):579-91
19478820
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):545-52
16168847
Oncogene. 2007 Jun 7;26(27):3941-51
17213816
Mol Pharmacol. 1998 Apr;53(4):795-800
9547373
J Med Chem. 2009 Dec 10;52(23):7868-72
19954250
Biochim Biophys Acta. 2007 Nov;1770(11):1520-7
17884296
J Biol Inorg Chem. 2008 Feb;13(2):289-302
18046586
Free Radic Biol Med. 2008 Jul 15;45(2):201-10
18457677
Neurosci Lett. 2009 Nov 27;466(1):41-6
19766169
Antioxid Redox Signal. 2009 Sep;11(9):2209-22
19203223
Neuroscience. 2009 Dec 1;164(2):702-10
19607887
Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):755-61
17272744
J Neurosci. 2001 Jul 1;21(13):4582-92
11425886
Free Radic Biol Med. 2002 Sep 15;33(6):857-63
12208373
Diabetes. 2004 Oct;53(10):2559-68
15448084
ACS Chem Biol. 2009 Mar 20;4(3):161-77
19267456
Nitric Oxide. 2000 Oct;4(5):526-33
11020341
Ann Neurol. 2005 Aug;58(2):258-65
16049935
Arch Biochem Biophys. 2005 Jul 15;439(2):234-40
15978540
Free Radic Biol Med. 2009 Aug 1;47(3):250-60
19389472
Cancer Cell. 2007 Sep;12(3):230-8
17785204
Mol Cell Biol. 1993 Feb;13(2):852-60
8423807
Amino Acids. 2012 Jan;42(1):139-58
20454814
Dose Response. 2008;6(3):223-38
18846257
Biochem Pharmacol. 2004 Jan 1;67(1):77-85
14667930
Nucleic Acids Res. 1992 Aug 11;20(15):3821-30
1508666
Oncogene. 2001 Apr 30;20(19):2390-400
11402335
Free Radic Biol Med. 2008 Oct 1;45(7):943-9
18598757
J Pharm Biomed Anal. 2009 Dec 5;50(5):1088-91
19660888
Arch Biochem Biophys. 2008 Sep 1;477(1):105-12
18477465
Free Radic Res. 2007 Nov;41(11):1273-82
17957541
J Biol Chem. 1998 Sep 18;273(38):24521-8
9733746
Cancer Cell. 2004 May;5(5):429-41
15144951
Cancer Res. 2005 Feb 15;65(4):1401-5
15735027
Diabetes. 2002 Feb;51(2):347-55
11812741
Arch Biochem Biophys. 1982 Apr 1;214(2):452-63
6284026
Antioxid Redox Signal. 2009 Sep;11(9):2223-43
19496701
Dalton Trans. 2004 Jun 7;(11):1696-702
15252564
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):573-80
17236973
Free Radic Biol Med. 2006 Sep 15;41(6):937-41
16934676
Free Radic Biol Med. 2009 Oct 1;47(7):992-1004
19591920
J Biol Chem. 2003 Jul 25;278(30):27432-8
12700236
Free Radic Biol Med. 2010 Apr 15;48(8):1034-43
20096348
Redox Rep. 2009;14(6):236-42
20003708
J Pharm Biomed Anal. 2008 Nov 4;48(3):1046-9
18804338
J Biol Chem. 2002 Nov 15;277(46):44548-56
12213807
Free Radic Biol Med. 2009 Jan 15;46(2):212-9
18983908
Biochem Pharmacol. 2003 Oct 15;66(8):1371-9
14555211
Free Radic Biol Med. 2009 Jan 15;46(2):192-201
19007878
Free Radic Biol Med. 2007 Apr 15;42(8):1193-200
17382200
Nucleic Acids Res. 1996 Jun 15;24(12):2236-42
8710491
Am J Med. 2000 Jun 1;108(8):652-9
10856414
Antioxid Redox Signal. 2010 Sep 15;13(6):877-918
20095865
J Immunol. 2002 Jan 15;168(2):825-33
11777978
Free Radic Biol Med. 2006 Aug 1;41(3):503-12
16843831
Antioxid Redox Signal. 2009 Mar;11(3):571-4
18715142
Cancer Res. 2009 Jul 1;69(13):5450-7
19549914
Free Radic Res. 2007 Jan;41(1):8-14
17164174
Int J Radiat Biol Relat Stud Phys Chem Med. 1982 Oct;42(4):449-56
6293987
Antioxid Redox Signal. 2009 Sep;11(9):2057-64
19422287
Free Radic Biol Med. 2007 May 15;42(10):1571-8
17448904